{
    "clinical_study": {
        "@rank": "53856", 
        "brief_summary": {
            "textblock": "To evaluate the mechanism whereby thymopentin appears to retard the progressive immune\n      suppression attributable to HIV infection."
        }, 
        "brief_title": "A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive subcutaneous thymopentin or placebo thrice weekly for 4\n      weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Asymptomatic or minimally symptomatic HIV infection (no evidence of AIDS).\n\n          -  CD4 count <= 400 cells/mm3 within 6 weeks prior to study entry (CD4 count changed to\n             100 - 400 cells/mm3 per amendment).\n\n          -  Tolerated the current nucleoside analog antiretroviral treatment for at least 4 weeks\n             prior to study entry.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Known hypersensitivity to thymopentin or any component of the formulation.\n\n          -  Significant chronic underlying medical illness that would impede study participation.\n\n          -  Grade 2 or higher peripheral neuropathy related to nucleoside analog antiretroviral\n             treatment.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Any antiretroviral agents other than zidovudine, didanosine, or dideoxycytidine.\n\n          -  HIV vaccines or any investigational or non-FDA approved medication or\n             immunomodulatory or experimental therapy within 30 days prior to study entry.\n\n        Patients with the following prior condition are excluded:\n\n        Abnormal chest x-ray consistent with active opportunistic infection within 6 weeks prior\n        to study entry.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Any prior antiretroviral agents other than zidovudine, didanosine, or dideoxycytidine\n             within 30 days prior to study entry.\n\n        Required:\n\n          -  Current nucleoside analog antiretroviral treatment.\n\n        Required:\n\n          -  Nucleoside analog antiretroviral treatment for at least 4 weeks prior to study entry.\n\n        Significant active alcohol or drug abuse sufficient to prevent study compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002332", 
            "org_study_id": "015I", 
            "secondary_id": "07.32.039-94"
        }, 
        "intervention": {
            "intervention_name": "Thymopentin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Thymopentin", 
                "Anti-HIV Agents"
            ]
        }, 
        "keyword": [
            "Thymopentin", 
            "AIDS-Related Complex"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Dr Marcus Conant"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tarzana", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91356"
                    }, 
                    "name": "Dr Jeffrey Galpin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15206"
                    }, 
                    "name": "Novum Inc"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Double-Blind Study of the Effect of Timunox (Thymopentin) on Lymphoproliferative Responses and Virus Load in HIV-Infected Subjects Receiving Nucleoside Analog Antiretroviral Therapy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002332"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Immunobiology Research Institute", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1995"
    }, 
    "geocoordinates": {
        "Dr Jeffrey Galpin": "34.149 -118.551", 
        "Dr Marcus Conant": "37.775 -122.419", 
        "Novum Inc": "40.441 -79.996"
    }
}